Coalition for Bone Marrow Failure Diseases | Aplastic Anemia and MDS International Foundation

Coalition for Bone Marrow Failure Diseases

In 2017, AAMDSIF established the Coalition for Bone Marrow Failure Disease – a growing partnership of the public private sector working together with the current U.S. policy and regulatory environment to respond to patients’ needs, build awareness, provide education and expand access to available therapeutic options for bone marrow failure both here and abroad. 

AAMDSIF serves as a convener of the Coalition whose ultimate vision is to grow awareness for bone marrow failure diseases and facilitate access to quality care for all patients. We aim to accomplish this with the Coalition serving as one voice for ensuring quality care options for bone marrow failure disease by:

  • Utilizing our combined strength to promote better treatments and advance research for bone marrow failure disease within the U.S. policy and regulatory environment; and
  • Creating global recognition and understanding of bone marrow failure disease so that research for better treatments and drugs continues.

Coalition Sponsors


Achillion Logo Consummate Capital Logo Geron Pharmaceuticals Logo Incyte Logo Jazz Pharmaceuticals Logo Ra Pharma Logo Takeda Oncology Logo

While many health professionals believe this is a critical time for research and development in the bone marrow failure space, AAMDSIF also recognizes the existence of certain obstacles to growth in this field. By forming the Coalition for Bone Marrow Failure Diseases, the Foundation has positioned itself to take the lead in breaking down those barriers so that our community of patients and families may be better served.

The Coalition will convene executive-level panel discussions with thought leaders, medical experts and clinical researchers to delve into such pressing issues as the lack of research funding to study these diseases - leading to slower product development that could improve treatments - and the ability of patients to access those treatments.

To ensure that these meetings are as impactful as possible, we are presenting them in moderated hour-long discussions, followed by 30-minute moderated Q&A sessions. Meeting participants and attendees will consist of representatives of academic and research institutions, leading philanthropists, and experts from the public and private sectors.

For more information, please contact Serap Akisoglu at akisoglu@aamds.org or 301-944-1072.